BioSpace News Archive

Imagin Medical (CSE:IME)today announced that it will host a virtual investor event with Key Opinion Leaders to highlight the game-changing potential of the i/Blue Imaging System on Thursday, October 29, 2020 at 12:00 pm Eastern Daylight Time.

LifeScan , a world leader in blood glucose monitoring and maker of the iconic OneTouch® brand, today announced the launch of its OneTouch Amazon storefront for people managing Type 1 and Type 2 diab

Research alliance will leverage advanced data analytics and genomic testing to improve recruitment of patients in oncology clinical trials

Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases, today announced that it has entered into a preferred provider network agreement with Provider Network of America (PNOA). Under the terms of the agreement, over 8 million PNOA members in the U.S. will have in-network access to Exagen’s unique suite of AVISE® tests for autoimmune disorders,

Hematological malignancies, commonly known as hematological cancer, is registering a widespread prevalence across the world.

The global osteoarthritis drugs market is expected to reach a market value of about US$ 11,226.1 Mn by the end of 2026, expanding at a high single digit CAGR during the forecast period.

A rapid rise in the use of spine surgical robots is attributed to a blend of technological improvements.

The global transplant diagnostic market is expanding due to the increasing number of patients emphasizing on early patient profiling during organ transplantation and rising adoption of transplant diagnostic techniques.

Veterinary vaccines are used to prevent and treat animal diseases. In terms of revenue, the global veterinary vaccines market was valued at almost US$ 6,100 Mn in 2017 and is anticipated to reach over US$ 12,000 Mn in 2026, expanding at a CAGR of above 6.5% from 2018 to 2026.

Immunovia, a diagnostic company that develops highly accurate blood tests for the early detection of cancer and autoimmune diseases, announced positive results from the verification study and will now commence the validation study, the last step towards the launch of IMMray™ PanCan-d.